###### Strengths and limitations of this study

-   Urinary C peptide creatinine ratio (UCPCR) is a valid method to assess insulin secretion in and outside pregnancy. We are the first to report the use of UCPCR to assess insulin sensitivity in pregnancy using a modified Matsuda equation.

-   A modified Matsuda equation using UCPCR provides a practical and non-invasive method to assess insulin sensitivity in pregnancy that could potentially be useful in epidemiological studies and clinical practice.

-   We have observed a hyperbolic relationship between fasting UCPCR values and insulin sensitivity, suggesting that UCPCR could be used to estimate β-cell function.

-   The study was conducted in pregnant women; therefore, the results cannot necessarily be extrapolated to a non-pregnant population.

Introduction {#s1}
============

In pregnancy, maternal normoglycaemia is dependent on insulin secretion increasing sufficiently to compensate for the physiological fall in insulin sensitivity (IS). In clinical practice, measuring insulin secretion is relatively straightforward using serum insulin, serum C peptide or the urinary C peptide.[@R1] Urinary C peptide creatinine ratio (UCPCR), obtained using the fasting second-void urine sample, is strongly correlated with serum insulin, serum C peptide[@R4] and 24 hours urinary C peptide,[@R4] providing a practical and non-invasive method to assess insulin secretion. By contrast, measuring IS is much more complex. The euglycaemic hyperinsulinaemic clamp, although the gold standard, is impractical for clinical use. The Matsuda Index (IS~OGTT~) provides a validated simpler alternative using serum glucose and insulin measurements during an oral glucose tolerance test (OGTT).[@R6] In pregnancy, the Matsuda Index exhibits a stronger correlation with the euglycaemic hyperinsulinaemic clamp, than other IS models (ie, HOMA-IR).[@R7] A modified Matsuda Index that substitutes serum C peptide for insulin has been validated during pregnancy.[@R8] Our previous work has shown that serum C peptide and UCPCR are strongly correlated during an OGTT in the latter half of pregnancy.[@R9] Using data collected during this study, we evaluate whether maternal UCPCR obtained during an OGTT can replace serum C peptide in the previous validated modified Matsuda Index of Radaelli *et al*.[@R8] We also evaluated the relationship between IS in the UCPCR-modified Matsuda equation and insulin secretion estimated by the second-void fasting UCPCR.

Research design and methods {#s1a}
---------------------------

The present study is a further analysis of a published prospective cross-sectional study undertaken in the maternity unit at Queen Charlotte's and Chelsea Hospital, London, UK.[@R9] All women had given informed written consent. The original database was from 100 women prospectively recruited who agreed to provide an extra blood and urine sample during their routine diagnostic 28-week 75 g OGTT for gestational diabetes mellitus (GDM). Women were recruited over a 5-month period in 2016. All women were either 35 years old or above, expecting twins or had one or more risk factors for GDM according to the National Institute for Health and Care Excellence (NICE) guidelines.[@R10] All women included had normal renal function. From the original dataset of 100 women, 27 were excluded from the current analysis, 2 with gestational age above 31 weeks, 1 with a renal transplant and 21 with urinary C peptide above the assay detection limit after automated 1:10 dilution. A further three women were not included in the final analysis due to missing 120 min UCPCR data.

All women attended the 2-hour 75 g OGTT fasted and had passed their overnight first void urine. Fasting and 2-hour blood samples were taken for plasma glucose and serum C peptide. Urine samples were collected at the beginning (second void urine) and end of the OGTT.

The blood glucose was collected in fluoride oxalate tubes and processed in the routine hospital laboratory using the hexokinase/G-6-phosphate dehydrogenase spectrophotometric method, with an imprecision of ≤5% of the total coefficient of variation (CV), performed on Abbott Architect c System. The C peptide blood sample was collected on ice, before centrifugation and the plasma stored in 1 mL cryotubes at −80°C.

The urinary C peptide was collected and stored in boric acid tubes before being aliquoted into 1 mL cryotubes and stored at −80°C. Urinary creatinine was assayed using the kinetic alkaline picrate method with a total CV of ≤6% (Abbott Architect ci16200 System) to obtain the UCPCR.

Urinary and serum C peptide were measured on an Abbott Diagnostics Architect platform (Abbott Laboratories, Abbott Park, Illinois, USA), using a two-step chemiluminescent microparticle immunoassay, with measurement ranges between 3.33 and 10 000 pmol/L. The Architect C peptide assay was designed to have a precision of ≤10% total CV. Automated dilution of 1:10 was performed in urine samples exceeding the upper limit of assay detection.

Calculation of IS was made using two different modified Matsuda equations. The first equation used serum C peptide, as previously validated in pregnancy by Radaelli *et al*,[@R8] ([box 1](#B1){ref-type="boxed-text"}). In the second equation, IS was calculated replacing serum C peptide for UCPCR values ([box 2](#B2){ref-type="boxed-text"}).Box 1Serum C peptide replaces serum insulin in the original Matsuda equation and 500 000 is used as the numeratorIS~OGTTC-pep~=500 000/√{\[FPGxFsC-pep\] × \[mean glucose × mean sC-pep during the OGTT\]}[^1] Box 2Urinary C peptide creatinine ratio (UCPCR) values at fasting and the mean UCPCR between 0 and 120 min replace the fasting and mean insulin values in the original Matsuda equation. 500 000 was also used here as the numeratorIS~OGTT-UCPCR~=500 000/√{\[FPG×FUCPCR\] × \[mean glucose × mean UCPCR during the OGTT\]}[^2]

Numeric data are presented as mean and SD, or median and IQR. Categorical data are shown as percentages. Data not normally distributed were log transformed for analysis. We evaluated the correlation between two modified Matsuda equations ([boxes 1 and 2](#B1 B2){ref-type="boxed-text"}) using Pearson correlations and linear regression analysis. A sensitivity analysis was performed excluding the four women with GDM.

The relationship between insulin secretion and IS displays a hyperbolic function.[@R11] To verify if the OGTT-based measures of insulin secretion and IS in this study displayed a hyperbolic relationship, the following regression analysis was performed: log(secretion measure)=constant + β × log(sensitivity measure). The criteria for a hyperbolic relationship were then applied: (1) β is approximately equal to −1 and (2) the 95% CI of β excludes 0.[@R12]

Statistical analysis was performed using SPSS V.22. A p value of \<0.05 was considered statistically significant.

Results {#s2}
=======

The 76 participant characteristics and their OGTT results are summarised in [table 1](#T1){ref-type="table"}.

###### 

Participants characteristics and oral glucose tolerance test (OGTT) results

  Characteristics               %, mean (±SD) or median (IQR)   n
  ----------------------------- ------------------------------- ----
  Maternal age (years)          34.1 (±4.7)                     76
  BMI (kg/m^2^)                 23.8 (5.8)                      76
  Ethnicity                                                     76
   Caucasian                    51.3%                           
   South Asian                  17.1%                           
   South East Asian             9.2%                            
   Middle Eastern               13.2%                           
   Black (African/Caribbean)    3.9%                            
   Other                        5.3%                            
  Parity                                                        76
   Nulliparous                  56.6%                           
   Multiparous                  43.4%                           
  Singleton pregnancy (yes)     94.6%                           76
  Gestational age (weeks)       28.0 (0.28)                     76
  OGTT results                                                  
   Fasting glucose (mmol/L)     4.4 (0.5)                       76
   Fasting C peptide (pmol/L)   0.48 (0.29)                     75
   Fasting UCPCR (pmol/mmol)    2.93 (2.02)                     75
   2-Hour glucose (mmol/L)      5.4 (1.9)                       76
   2-Hour C peptide (pmol/L)    2.12 (1.14)                     75
   2-Hour UCPCR (pmol/mmol)     12.06 (11.4)                    73
   GDM (yes)                    5.3%                            76

BMI, body mass index; GDM, gestational diabetes mellitus; UCPCR, urinary C peptide creatinine ratio.

The median estimates for IS~OGTTc-pep~ and IS~OGTT-UCPCR~ were 8.1 (2.5--22.4) and 1.2 (0.3--9.3), respectively.

The two IS indexes calculated (IS~OGTTc-pep~ and IS~OGTT-UCPCR~) were significantly correlated (r=0.704, p\<0.0001) The linear regression model is summarised in [figure 1A](#F1){ref-type="fig"}.

![Linear regression models for IS~OGTTc-pep~ and IS~OGTT-UCPCR~: (A) in the full cohort: Y=0.833+0.496X, r=0.704, p\<0.001 and (B) excluding women with gestational diabetes mellitus (GDM): Y=0.851+0.436X, r=0.654, p\<0.001. IS, insulin sensitivity; OGTT, oral glucose tolerance test; UCPCR, urinary C peptide creatinine ratio.](bmjopen-2017-020029f01){#F1}

The association between IS~OGTTc-pep~ and IS~OGTT-UCPCR~ remained significant after excluding the four women with GDM in the sensitivity analysis (r=0.654, p\<0.0001). The linear regression model is summarised in [figure 1](#F1){ref-type="fig"}B.

The IS~OGTT-UCPCR~ showed a strong correlation with both the fasting and the 120 min UCPCR (r=−0.916, p\<0.0001) (r=−0.777, p\<0.0001), respectively. A hyperbolic plot pattern was observed between IS~OGTT-UCPCR~ and both, fasting and 120 min UCPCR ([figure 2A, B](#F2){ref-type="fig"}). The four women who had GDM by NICE criteria fell on the left-hand side of this hyperbola in both graphs.

![Correlation plot patterns between (A) IS~OGTT-UCPCR~ and the fasting urinary C peptide creatinine ratio (UCPCR) and (B) IS~OGTT-UCPCR~ and the 2-hour UCPCR. Women with gestational diabetes mellitus (GDM) are highlighted in black. IS, insulin sensitivity; OGTT, oral glucose tolerance test.](bmjopen-2017-020029f02){#F2}

A hyperbolic relationship was displayed between IS~OGTT-UCPCR~ and the fasting UCPCR (β −1.002, 95% CI −1.105 to -- 0.898, p\<0.001) ([figure 3A](#F3){ref-type="fig"}).

![Hyperbolic relationship displayed between IS~OGTT-UCPCR~ and the fasting urinary C peptide creatinine ratio (UCPCR): (A) in the full study cohort and (B) excluding the four women with GDM. IS, insulin sensitivity; OGTT, oral glucose tolerance test.](bmjopen-2017-020029f03){#F3}

In the sensitivity analysis, excluding the four women with GDM, both of the hyperbolic criteria were consistent with the existence of a hyperbolic relationship between these two measures (β −1.019, 95% CI −1.132 to −0.907, p\<0.001) ([figure 3B](#F3){ref-type="fig"}).

However, the relationship between IS~OGTT-UCPCR~ and the 120 min UCPCR did not fulfil the hyperbolic function criteria (β −0.767).

Discussion {#s3}
==========

In this study, IS in pregnant women was calculated using two different modifications to the original Matsuda equations that replaced serum insulin in the original equation for either serum C peptide or UCPCR. The indexes calculated by both methods were well correlated. In pregnancy, the Matsuda equation using serum C peptide has been validated against the original method described by Matsuda using serum insulin.[@R8] Furthermore, in pregnancy, it has shown a better correlation with IS derived using the euglycaemic hyperinsulinaemic clamp than Homeostasis assessment model - insulin resistance (HOMA-IR).[@R7] This may be as HOMA-IR is highly dependent on basal hepatic insulin resistance[@R6] rather than total glucose disposal which will include maternal and fetal glucose uptake.

The use of the UCPCR provides a more convenient and practical method of assessing insulin secretion, as it is stable at room temperature for 3 days.[@R4] UCPCR has proven to be a robust tool to assess insulin secretion, having a good correlation with both circulating insulin concentrations and serum C peptide.[@R5] The fasting second-void urine UCPCR reflects an integrated measurement over time that has shown to be strongly correlated with 24 hours urinary C peptide measurements.[@R4] Our current results show that UCPCR provides an estimate of insulin secretion and it can, in a modified Matsuda equation, be used to assess IS.

A hyperbolic relationship was observed between IS~OGTT-UCPCR~ and the fasting UCPCR, in our study. This mirrors the hyperbolic relationship that defines the Disposition Index (DI), the product of insulin secretion and IS,[@R11] which has been proposed as a measure of β-cell compensatory capacity, in both pregnant[@R14] and non-pregnant subjects.[@R12]

The utility of the DI as a measure of β-cell function was defined by the hyperbolic relationship between insulin secretion and IS derived from the intravenous glucose tolerance test.[@R15] More recently, this relationship has been observed using parameters derived from the OGTT.[@R13] Our work suggests that UCPCR substituted into the Matsuda equation can also offer information regarding β-cell function during pregnancy.

It has been established that women entering pregnancy with decreased IS are more at risk of developing GDM.[@R16] UCPCR, as an easy and non-invasive clinical method to assess IS, could potentially help identify women most at risk of developing GDM in early pregnancy, allowing targeted lifestyle modification to lessen the risk of GDM. There is increasing evidence that lifestyle and therapeutic intervention after 18 weeks of pregnancy in at-risk women has little effect on preventing both GDM and fetal macrosomia.[@R17] By contrast, earlier intervention with diet and physical activity may have a beneficial role.[@R20]

A practical and accurate method to estimate IS in pregnancy could also be informative in better understanding the epigenetic impact of maternal obesity and glucose homeostasis on the fetus.[@R21]

A limitation of this study is that all women included had one or more risk factors for GDM. The study was conducted in pregnant women and therefore the results cannot necessarily be extrapolated to the non-pregnant population. Further studies on a larger scale are needed to corroborate these findings and confirm whether UCPCR could potentially be used to assess an individual's risk for developing GDM.

In summary, we have shown that the UCPCR-derived Matsuda Index in pregnancy is correlated with the serum C peptide-derived index, as validated by Radaelli *et al*. The relationship between IS estimated by the UCPCR-derived Matsuda equation and the fasting and post-OGTT UCPCR showed a hyperbolic relationship that suggests that this measurement could be useful to assess β-cell compensatory capacity in pregnancy.
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